Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

This study is testing HRS9531, a new injectable medication, in people with type 2 diabetes who are already on daily basal insulin. The goal is to see whether adding HRS9531 can further lower blood sugar levels and potentially reduce the amount of insulin needed. **You may be eligible if...** - You are an adult (male or female) with type 2 diabetes diagnosed at least 90 days ago - You are currently on a stable daily dose of basal insulin alone or combined with metformin and/or an SGLT2 inhibitor (like empagliflozin or dapagliflozin) - Your HbA1c (a measure of average blood sugar over 3 months) is between 7.5% and 11.0% - Your BMI is 22 or higher **You may NOT be eligible if...** - You have type 1 diabetes - You are on other diabetes medications beyond basal insulin, metformin, or SGLT2 inhibitors - You have a history of pancreatitis or thyroid tumors - You have significant kidney, liver, or heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.